Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1021958 in Healthy Chinese and Japanese Male Volunteers (Placebo-controlled, Randomised and Double-blind Within Dose Groups)
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2016
At a glance
- Drugs BI 1021958 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 22 Aug 2012 Actual end date Aug 2012 added as reported by ClinicalTrials.gov.
- 01 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.